Navigation Links
Mouse Model Beneficial to Study of Head and Neck Cancer

The development of a mouse model by the Oregon Health & Science University Cancer Institute research laboratory has proved beneficial in the study of the often devastating// head and neck squamous cell cancers.

The research was conducted by Xiao-Jing Wang, M.D., Ph.D., and his colleagues. The results of their research breakthrough have been published in the May 15 issue of Genes & Development.

‘This is the first animal model that mimics human head and neck cancer at both the pathological and the molecular levels with 100 percent incidence,’ Wang said.

While scientists have identified some genes involved in head and neck squamous (HNSCC)cell carcinoma , overall, progress has been hampered by the lack of an animal model to study the development and progression of the disease. ‘This model will provide a valuable tool to screen for novel therapeutic and preventive approaches for this often deadly cancer,’ said Wang, head of the Division of Molecular Biology of Head and Neck Cancer in the OHSU School of Medicine and a member of the OHSU Cancer Institute.

Head and neck squamous cell carcinoma is the sixth most common cancer in the United States. It has a low survival rate - fewer than 50 percent of head and neck patients survive beyond five years, and this rate has not changed in the past 20 years, despite progress in developing therapies for other cancers. Patients are usually resistant to routine chemotherapy and radiation therapy. In addition, the quality of life for survivors is usually miserable because the location of the cancer often destroys structures critical to speaking, breathing and swallowing.

In their research, Wang and her colleagues engineered a strain of mice to specifically lack expression of the transforming growth factor beta receptor II (TGFbRII) in epithelial cells of the oral cavity. By then introducing activating mutations in either the H-ras or K-ras (two different isoforms of the Ras GTPase), t he researchers were able to induce invasive HNSCC with 100 percent incidence.

‘Head and neck lesions developed from this mouse model have many molecular alterations similar to those found in HNSCC patients. Additionally, we have identified several new biomarkers that data suggest may be good targets for HNSCC therapy,’ Wang said.

Wang was recruited to OHSU to study head and neck cancers. Through her research and through personal acquaintances, her passion was stirred to help people with this type of disfiguring cancer.

‘Before I came to OHSU, a woman who was helping me here with my new house asked what was bringing me to Portland.

When I told her it was to lead OHSU's research on head and neck cancer, she said, 'Oh, my god, we were meant to meet. My husband was just diagnosed with head and neck cancer.' During my interactions with her after we moved to Portland, I realized how much this disease impacts patients and their family members. Then, only a few months later, a family friend was diagnosed with head and neck cancer. These two cases made me realize that this terrible disease could happen to people all around us, even our loved ones, and inspired me to my best effort in leading this study,’ Wang said.

‘It was a true team effort of the head and neck cancer research division, especially with Dr. Shilong Lu, the first author on this study, who made the major contribution to this model,’ Wang said. Shilong LU, M.D., Ph.D., is research assistant professor of otolaryngology/head and neck surgery in the OHSU School of Medicine.

Peter Andersen, M.D., F.A.C.S., associate professor of otolaryngology/head and neck surgery in the OHSU School of Medicine; and Christopher L. Corless, M.D., professor of pathology in the OHSU School of Medicine, and member of the OHSU Cancer Institute, are co-authors on this study.

Source: Eurealert
'"/>




Related medicine news :

1. Mouse Allergen Found In Homes Could Trigger Asthma In Kids
2. Researchers Develop Mouse Model Of Brain Tumor
3. German Scientists Create Stem Cells From Mouse Testes
4. Mouse Models To Determine The Cause Of Aggressive Leukemia
5. Scientists Discover New RNAs in Mouse Testicles
6. Scientists Isolate Leukemia Stem Cells in Mouse Model
7. Mouse Model Demonstrates Immune System Reaction In Chlamydia Infection
8. Mouse Gene With Gene Stutter Will Help Leukemia Research
9. Rett Syndrome Reversed in Genetic Mouse Model
10. Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy
11. Mouse Study Suggests Anxiety Disorders Take Root in Infancy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: